Aladorian
Based on 1 Customer Validation
Aladorian (ARM036; S44121) is a non-peptidic ryanodine receptor 2 (RyR2) stabilizer. Aladorian stabilizes RyR2 channels and rectifies abnormal Ca²⁺ handling in cardiomyocytes. Aladorian improves cardiomyocyte Ca²⁺ homeostasis independent of dystrophin restoration. Aladorian attenuates early cardiomyopathy and enhances left ventricular function in a canine muscular dystrophy model. Aladorian can be used for the research of heart failure, Duchenne muscular dystrophy-associated cardiomyopathy and muscular dystrophy.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.31%
- CAS. Nr.: 865433-00-7
- Formel: C12H13NO4S
- Molecular Weight:267.30
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Calcium Channel |
Aladorian (ARM036) produces a characteristic product ion mass spectrum when analyzed via high resolution/high accuracy mass spectrometry at a collision energy of 25 eV, with its protonated molecular ion detected at m/z 268.0639[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 865433-00-7
-
Appearance Solid
-
Molecular Weight 267.30
-
Formel C12H13NO4S
-
Color White to light yellow
-
SMILES
O=C(C(N1CCSC2=CC=C(C=C2C1)OC)=O)O
-
Synonyms
ARM036; S44121
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (374.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (18.71 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (18.71 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Luo M, et al. Mechanisms of altered Ca²⁺ handling in heart failure. Circ Res. 2013;113(6):690-708. [Content Brief]
[2]. Kupatt C, et al. Ryanodine Receptors Matter for Cardiac Function in Duchenne Muscular Dystrophy: Stability First. J Am Coll Cardiol. 2021 Dec 14;78(24):2454-2456. [Content Brief]
[5]. Thevis M, et al. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014;101:66-83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7411 mL | 18.7056 mL | 37.4112 mL | 93.5279 mL |
| 5 mM | 0.7482 mL | 3.7411 mL | 7.4822 mL | 18.7056 mL | |
| 10 mM | 0.3741 mL | 1.8706 mL | 3.7411 mL | 9.3528 mL | |
| 15 mM | 0.2494 mL | 1.2470 mL | 2.4941 mL | 6.2352 mL | |
| 20 mM | 0.1871 mL | 0.9353 mL | 1.8706 mL | 4.6764 mL | |
| 25 mM | 0.1496 mL | 0.7482 mL | 1.4964 mL | 3.7411 mL | |
| 30 mM | 0.1247 mL | 0.6235 mL | 1.2470 mL | 3.1176 mL | |
| 40 mM | 0.0935 mL | 0.4676 mL | 0.9353 mL | 2.3382 mL | |
| 50 mM | 0.0748 mL | 0.3741 mL | 0.7482 mL | 1.8706 mL | |
| 60 mM | 0.0624 mL | 0.3118 mL | 0.6235 mL | 1.5588 mL | |
| 80 mM | 0.0468 mL | 0.2338 mL | 0.4676 mL | 1.1691 mL | |
| 100 mM | 0.0374 mL | 0.1871 mL | 0.3741 mL | 0.9353 mL |
Aladorian Related Classifications
HY-119850 Related Classifications
Powered by Bioz
- Aladorian
- 865433-00-7
- ARM036
- S44121
- ARM 036
- ARM-036
- S44121
- S 44121
- S-44121
- Calcium Channel
- RyR1
- duchenne muscular dystrophy-associated cardiomyopathy
- RyR2
- cardiomyocytes
- calstabin1
- skeletal muscle cells
- heart failure
- golden retrievers
- FKBP12.6
- catecholaminergic polymorphic ventricular tachycardia
- Inhibitor
- inhibitor
- inhibit